These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 32545828)

  • 1. Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System.
    De Kleijn KMA; Martens GJM
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL; Tyor WR
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and future therapies targeting the immune system in multiple sclerosis.
    Loleit V; Biberacher V; Hemmer B
    Curr Pharm Biotechnol; 2014; 15(3):276-96. PubMed ID: 24938888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
    Kemmerer CL; Pernpeintner V; Ruschil C; Abdelhak A; Scholl M; Ziemann U; Krumbholz M; Hemmer B; Kowarik MC
    PLoS One; 2020; 15(7):e0235449. PubMed ID: 32716916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
    Pistono C; Osera C; Boiocchi C; Mallucci G; Cuccia M; Bergamaschi R; Pascale A
    Pharmacol Res; 2017 Jun; 120():279-293. PubMed ID: 28396093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Effects of MS Therapeutics on B Cells-Implications for Their Use and Failure in AQP4-Positive NMOSD Patients.
    Traub J; Häusser-Kinzel S; Weber MS
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Siponimod (BAF312) Activates Nrf2 While Hampering NFκB in Human Astrocytes, and Protects From Astrocyte-Induced Neurodegeneration.
    Colombo E; Bassani C; De Angelis A; Ruffini F; Ottoboni L; Comi G; Martino G; Farina C
    Front Immunol; 2020; 11():635. PubMed ID: 32322257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune therapy of multiple sclerosis--future strategies.
    Meuth SG; Göbel K; Wiendl H
    Curr Pharm Des; 2012; 18(29):4489-97. PubMed ID: 22612746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Agents for Relapsing Forms of Multiple Sclerosis.
    Straus Farber R; Harel A; Lublin F
    Annu Rev Med; 2016; 67():309-21. PubMed ID: 26394285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New and emerging immune-targeted drugs for the treatment of multiple sclerosis.
    Palmer AM
    Br J Clin Pharmacol; 2014 Jul; 78(1):33-43. PubMed ID: 24251808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological Aspects of Approved MS Therapeutics.
    Rommer PS; Milo R; Han MH; Satyanarayan S; Sellner J; Hauer L; Illes Z; Warnke C; Laurent S; Weber MS; Zhang Y; Stuve O
    Front Immunol; 2019; 10():1564. PubMed ID: 31354720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances in the Treatment for Multiple Sclerosis; Current New Drugs Specific for Multiple Sclerosis.
    TaŞKapilioĞLu Ö
    Noro Psikiyatr Ars; 2018; 55(Suppl 1):S15-S20. PubMed ID: 30692849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview.
    Rommer PS; Zettl UK; Kieseier B; Hartung HP; Menge T; Frohman E; Greenberg BM; Hemmer B; Stüve O
    Clin Exp Immunol; 2014 Mar; 175(3):397-407. PubMed ID: 24102425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulating acute neuroinflammation in intracerebral hemorrhage: the potential promise of currently approved medications for multiple sclerosis.
    Napier J; Rose L; Adeoye O; Hooker E; Walsh KB
    Immunopharmacol Immunotoxicol; 2019 Feb; 41(1):7-15. PubMed ID: 30702002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010.
    Faissner S; Gold R
    CNS Drugs; 2018 Mar; 32(3):269-287. PubMed ID: 29600441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current immunotherapy of multiple sclerosis].
    Paul F; Ruprecht K
    Nervenarzt; 2015 Aug; 86(8):1031-42; quiz 1043-4. PubMed ID: 26253589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-modifying agents in multiple sclerosis.
    O'Connor PW; Oh J
    Handb Clin Neurol; 2014; 122():465-501. PubMed ID: 24507532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.